Asia
Newland Pharmaceutical Gets Registration Certificate for Moxifloxacin Hydrochloride Tablets
Newland Pharmaceutical (SHE:301277) received a drug registration certificate from China's National Medical Products Administration for its moxifloxacin hydrochloride tablets, according to a Shenzhen bourse filing on Monday.The pharmaceutical company's shares rose by less than 2% at the close of Monday's trade.The drug is used to treat infections caused by susceptible bacteria, such as acute bacterial sinusitis, pneumonia, chronic bronchitis, and skin infections.The certificate is valid until May 11, 2031.
SHE:301277
